Poland· PL-100499991
Ocrevus
A medicinal product containing ocrelizumabum, registered in Poland by Roche Registration GmbH.
Checked against URPL (Poland) on
Informational only — not a medical device.
The record
At a glance
URPL (Poland)- Active substance
- Ocrelizumabum
- Manufacturer
- Roche Registration GmbH
- Country
- Poland (PL)
- ATC code
- —
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 1
- gtin07613326075824
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Ocrelizumabum in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- SwitzerlandOcrevus subkutan 920 mg/23 ml, InjektionslösungRoche Pharma (Schweiz) AG
- FinlandOcrevusRoche Registration GmbH
- United KingdomOcrevus 300mg/10ml concentrate for solution for infusion vialsRoche Products Ltd
- CzechiaOCREVUSRoche Registration GmbH, Grenzach-Wyhlen
- FranceOCREVUS 300 mg, solution à diluer pour perfusionROCHE REGISTRATION (ALLEMAGNE)
- BelgiumOcrevus 300 mgRoche Registration
- SpainOCREVUS 300 MG CONCENTRADO PARA SOLUCION PARA PERFUSIONRoche Registration Gmbh
- IrelandOcrevus 300 mg concentrate for solution for infusionRoche Registration GmbH
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Ocrevus
- Liechtenstein · Ocrevus
- Norway · Ocrevus
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/0145db93-5a43-49a2-b075-d5f84702f0ff GET /v1/drugs/0145db93-5a43-49a2-b075-d5f84702f0ff?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Roztwór do wstrzykiwań",
"source": "urpl",
"strength": "40 mg/ml",
"packaging": "07613326075824 ¦ Rpz ¦ EU/1/17/1231/003 ¦ 157058\n1 fiol. 23 ml",
"substance": "Ocrelizumabum 40 mg/ml",
"common_name": "Ocrelizumabum",
"pl_product_id": "100499991",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about ocrelizumabum.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.